Loading…

Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer

Sentinel lymph node (SLN) mapping is becoming an acceptable alternative to full lymphadenectomy for evaluating lymphatic spread in clinical stage I endometrial cancer (EC). While the assessment of pelvic and para-aortic lymph nodes is part of the surgical staging of EC, there is a long-standing deba...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2022-02, Vol.29 (2), p.1123-1135
Main Authors: Salman, Lina, Cusimano, Maria C, Marchocki, Zibi, Ferguson, Sarah E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-de9a075effeeb0a92dd9cf937a50852c4efab454df747f472e5df4b529f5098f3
cites cdi_FETCH-LOGICAL-c465t-de9a075effeeb0a92dd9cf937a50852c4efab454df747f472e5df4b529f5098f3
container_end_page 1135
container_issue 2
container_start_page 1123
container_title Current oncology (Toronto)
container_volume 29
creator Salman, Lina
Cusimano, Maria C
Marchocki, Zibi
Ferguson, Sarah E
description Sentinel lymph node (SLN) mapping is becoming an acceptable alternative to full lymphadenectomy for evaluating lymphatic spread in clinical stage I endometrial cancer (EC). While the assessment of pelvic and para-aortic lymph nodes is part of the surgical staging of EC, there is a long-standing debate over the therapeutic value of full lymphadenectomy in this setting. Although lymphadenectomy offers critical information on lymphatic spread and prognosis, most patients will not derive oncologic benefit from this procedure as the majority of patients do not have lymph node involvement. SLN mapping offers prognostic information while simultaneously avoiding the morbidity associated with an extensive and often unnecessary lymphadenectomy. A key factor in the decision making when planning for EC surgery is the histologic subtype. Since the risk of lymphatic spread is less than 5% in low-grade EC, these patients might not benefit from lymph node assessment. Nonetheless, in high-grade EC, the risk for lymph node metastases is much higher (20-30%); therefore, it is crucial to determine the spread of disease both for determining prognosis and for tailoring the appropriate adjuvant treatment. Studies on the accuracy of SLN mapping in high-grade EC have shown a detection rate of over 90%. The available evidence supports adopting the SLN approach as an accurate method for surgical staging. However, there is a paucity of prospective data on the long-term oncologic outcome for patients undergoing SLN mapping in high-grade EC, and more trials are warranted to answer this question.
doi_str_mv 10.3390/curroncol29020096
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_42aed59a04064596b4233272b0b12984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_42aed59a04064596b4233272b0b12984</doaj_id><sourcerecordid>2632802086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-de9a075effeeb0a92dd9cf937a50852c4efab454df747f472e5df4b529f5098f3</originalsourceid><addsrcrecordid>eNplkU1P3DAQhq0KVOi2P6CXKkcuKY4_YluqkNCKAtICB9qz5djjXaPETp0sEv--prsgUE8zmnnnmRm9CH1t8HdKFT6125xTtKknChOMVfsBHTeikbUQRB28yY_Qp2l6wJhSIcRHdER5kXPFj9GPe4hziNBXq6dh3FS3yUF1Y8YxxHUVYnUV1pv6MptSvYguDTDnYPpqaaKF_BkdetNP8GUfF-j3z4tfy6t6dXd5vTxf1Za1fK4dKIMFB-8BOmwUcU5Zr6gwHEtOLANvOsaZ84IJzwQB7jzrOFGeYyU9XaDrHdcl86DHHAaTn3QyQf8rpLzWJs_B9qAZMeB42cdwy7hqO0YoJYJ0uGuIkqywznascdsN4Gx5P5v-HfR9J4aNXqdHLaXALZYFcLIH5PRnC9OshzBZ6HsTIW0nTVpKZLFDtkXa7KQ2p2nK4F_XNFg_O6j_c7DMfHt73-vEi2X0L9tcmTc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2632802086</pqid></control><display><type>article</type><title>Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer</title><source>PubMed Central database</source><creator>Salman, Lina ; Cusimano, Maria C ; Marchocki, Zibi ; Ferguson, Sarah E</creator><creatorcontrib>Salman, Lina ; Cusimano, Maria C ; Marchocki, Zibi ; Ferguson, Sarah E</creatorcontrib><description>Sentinel lymph node (SLN) mapping is becoming an acceptable alternative to full lymphadenectomy for evaluating lymphatic spread in clinical stage I endometrial cancer (EC). While the assessment of pelvic and para-aortic lymph nodes is part of the surgical staging of EC, there is a long-standing debate over the therapeutic value of full lymphadenectomy in this setting. Although lymphadenectomy offers critical information on lymphatic spread and prognosis, most patients will not derive oncologic benefit from this procedure as the majority of patients do not have lymph node involvement. SLN mapping offers prognostic information while simultaneously avoiding the morbidity associated with an extensive and often unnecessary lymphadenectomy. A key factor in the decision making when planning for EC surgery is the histologic subtype. Since the risk of lymphatic spread is less than 5% in low-grade EC, these patients might not benefit from lymph node assessment. Nonetheless, in high-grade EC, the risk for lymph node metastases is much higher (20-30%); therefore, it is crucial to determine the spread of disease both for determining prognosis and for tailoring the appropriate adjuvant treatment. Studies on the accuracy of SLN mapping in high-grade EC have shown a detection rate of over 90%. The available evidence supports adopting the SLN approach as an accurate method for surgical staging. However, there is a paucity of prospective data on the long-term oncologic outcome for patients undergoing SLN mapping in high-grade EC, and more trials are warranted to answer this question.</description><identifier>ISSN: 1718-7729</identifier><identifier>ISSN: 1198-0052</identifier><identifier>EISSN: 1718-7729</identifier><identifier>DOI: 10.3390/curroncol29020096</identifier><identifier>PMID: 35200595</identifier><language>eng</language><publisher>Switzerland: MDPI</publisher><subject>endometrial cancer ; Endometrial Neoplasms - pathology ; Endometrial Neoplasms - surgery ; Female ; high-grade ; Humans ; Neoplasm Staging ; Prospective Studies ; Review ; sentinel lymph node ; Sentinel Lymph Node - pathology ; Sentinel Lymph Node - surgery ; Sentinel Lymph Node Biopsy - methods</subject><ispartof>Current oncology (Toronto), 2022-02, Vol.29 (2), p.1123-1135</ispartof><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-de9a075effeeb0a92dd9cf937a50852c4efab454df747f472e5df4b529f5098f3</citedby><cites>FETCH-LOGICAL-c465t-de9a075effeeb0a92dd9cf937a50852c4efab454df747f472e5df4b529f5098f3</cites><orcidid>0000-0002-1661-4846</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870608/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870608/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35200595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salman, Lina</creatorcontrib><creatorcontrib>Cusimano, Maria C</creatorcontrib><creatorcontrib>Marchocki, Zibi</creatorcontrib><creatorcontrib>Ferguson, Sarah E</creatorcontrib><title>Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer</title><title>Current oncology (Toronto)</title><addtitle>Curr Oncol</addtitle><description>Sentinel lymph node (SLN) mapping is becoming an acceptable alternative to full lymphadenectomy for evaluating lymphatic spread in clinical stage I endometrial cancer (EC). While the assessment of pelvic and para-aortic lymph nodes is part of the surgical staging of EC, there is a long-standing debate over the therapeutic value of full lymphadenectomy in this setting. Although lymphadenectomy offers critical information on lymphatic spread and prognosis, most patients will not derive oncologic benefit from this procedure as the majority of patients do not have lymph node involvement. SLN mapping offers prognostic information while simultaneously avoiding the morbidity associated with an extensive and often unnecessary lymphadenectomy. A key factor in the decision making when planning for EC surgery is the histologic subtype. Since the risk of lymphatic spread is less than 5% in low-grade EC, these patients might not benefit from lymph node assessment. Nonetheless, in high-grade EC, the risk for lymph node metastases is much higher (20-30%); therefore, it is crucial to determine the spread of disease both for determining prognosis and for tailoring the appropriate adjuvant treatment. Studies on the accuracy of SLN mapping in high-grade EC have shown a detection rate of over 90%. The available evidence supports adopting the SLN approach as an accurate method for surgical staging. However, there is a paucity of prospective data on the long-term oncologic outcome for patients undergoing SLN mapping in high-grade EC, and more trials are warranted to answer this question.</description><subject>endometrial cancer</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Endometrial Neoplasms - surgery</subject><subject>Female</subject><subject>high-grade</subject><subject>Humans</subject><subject>Neoplasm Staging</subject><subject>Prospective Studies</subject><subject>Review</subject><subject>sentinel lymph node</subject><subject>Sentinel Lymph Node - pathology</subject><subject>Sentinel Lymph Node - surgery</subject><subject>Sentinel Lymph Node Biopsy - methods</subject><issn>1718-7729</issn><issn>1198-0052</issn><issn>1718-7729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNplkU1P3DAQhq0KVOi2P6CXKkcuKY4_YluqkNCKAtICB9qz5djjXaPETp0sEv--prsgUE8zmnnnmRm9CH1t8HdKFT6125xTtKknChOMVfsBHTeikbUQRB28yY_Qp2l6wJhSIcRHdER5kXPFj9GPe4hziNBXq6dh3FS3yUF1Y8YxxHUVYnUV1pv6MptSvYguDTDnYPpqaaKF_BkdetNP8GUfF-j3z4tfy6t6dXd5vTxf1Za1fK4dKIMFB-8BOmwUcU5Zr6gwHEtOLANvOsaZ84IJzwQB7jzrOFGeYyU9XaDrHdcl86DHHAaTn3QyQf8rpLzWJs_B9qAZMeB42cdwy7hqO0YoJYJ0uGuIkqywznascdsN4Gx5P5v-HfR9J4aNXqdHLaXALZYFcLIH5PRnC9OshzBZ6HsTIW0nTVpKZLFDtkXa7KQ2p2nK4F_XNFg_O6j_c7DMfHt73-vEi2X0L9tcmTc</recordid><startdate>20220214</startdate><enddate>20220214</enddate><creator>Salman, Lina</creator><creator>Cusimano, Maria C</creator><creator>Marchocki, Zibi</creator><creator>Ferguson, Sarah E</creator><general>MDPI</general><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1661-4846</orcidid></search><sort><creationdate>20220214</creationdate><title>Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer</title><author>Salman, Lina ; Cusimano, Maria C ; Marchocki, Zibi ; Ferguson, Sarah E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-de9a075effeeb0a92dd9cf937a50852c4efab454df747f472e5df4b529f5098f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>endometrial cancer</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Endometrial Neoplasms - surgery</topic><topic>Female</topic><topic>high-grade</topic><topic>Humans</topic><topic>Neoplasm Staging</topic><topic>Prospective Studies</topic><topic>Review</topic><topic>sentinel lymph node</topic><topic>Sentinel Lymph Node - pathology</topic><topic>Sentinel Lymph Node - surgery</topic><topic>Sentinel Lymph Node Biopsy - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salman, Lina</creatorcontrib><creatorcontrib>Cusimano, Maria C</creatorcontrib><creatorcontrib>Marchocki, Zibi</creatorcontrib><creatorcontrib>Ferguson, Sarah E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Current oncology (Toronto)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salman, Lina</au><au>Cusimano, Maria C</au><au>Marchocki, Zibi</au><au>Ferguson, Sarah E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer</atitle><jtitle>Current oncology (Toronto)</jtitle><addtitle>Curr Oncol</addtitle><date>2022-02-14</date><risdate>2022</risdate><volume>29</volume><issue>2</issue><spage>1123</spage><epage>1135</epage><pages>1123-1135</pages><issn>1718-7729</issn><issn>1198-0052</issn><eissn>1718-7729</eissn><abstract>Sentinel lymph node (SLN) mapping is becoming an acceptable alternative to full lymphadenectomy for evaluating lymphatic spread in clinical stage I endometrial cancer (EC). While the assessment of pelvic and para-aortic lymph nodes is part of the surgical staging of EC, there is a long-standing debate over the therapeutic value of full lymphadenectomy in this setting. Although lymphadenectomy offers critical information on lymphatic spread and prognosis, most patients will not derive oncologic benefit from this procedure as the majority of patients do not have lymph node involvement. SLN mapping offers prognostic information while simultaneously avoiding the morbidity associated with an extensive and often unnecessary lymphadenectomy. A key factor in the decision making when planning for EC surgery is the histologic subtype. Since the risk of lymphatic spread is less than 5% in low-grade EC, these patients might not benefit from lymph node assessment. Nonetheless, in high-grade EC, the risk for lymph node metastases is much higher (20-30%); therefore, it is crucial to determine the spread of disease both for determining prognosis and for tailoring the appropriate adjuvant treatment. Studies on the accuracy of SLN mapping in high-grade EC have shown a detection rate of over 90%. The available evidence supports adopting the SLN approach as an accurate method for surgical staging. However, there is a paucity of prospective data on the long-term oncologic outcome for patients undergoing SLN mapping in high-grade EC, and more trials are warranted to answer this question.</abstract><cop>Switzerland</cop><pub>MDPI</pub><pmid>35200595</pmid><doi>10.3390/curroncol29020096</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-1661-4846</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1718-7729
ispartof Current oncology (Toronto), 2022-02, Vol.29 (2), p.1123-1135
issn 1718-7729
1198-0052
1718-7729
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_42aed59a04064596b4233272b0b12984
source PubMed Central database
subjects endometrial cancer
Endometrial Neoplasms - pathology
Endometrial Neoplasms - surgery
Female
high-grade
Humans
Neoplasm Staging
Prospective Studies
Review
sentinel lymph node
Sentinel Lymph Node - pathology
Sentinel Lymph Node - surgery
Sentinel Lymph Node Biopsy - methods
title Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T07%3A08%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sentinel%20Lymph%20Node%20Mapping%20in%20High-Grade%20Endometrial%20Cancer&rft.jtitle=Current%20oncology%20(Toronto)&rft.au=Salman,%20Lina&rft.date=2022-02-14&rft.volume=29&rft.issue=2&rft.spage=1123&rft.epage=1135&rft.pages=1123-1135&rft.issn=1718-7729&rft.eissn=1718-7729&rft_id=info:doi/10.3390/curroncol29020096&rft_dat=%3Cproquest_doaj_%3E2632802086%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-de9a075effeeb0a92dd9cf937a50852c4efab454df747f472e5df4b529f5098f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2632802086&rft_id=info:pmid/35200595&rfr_iscdi=true